Searchable abstracts of presentations at key conferences in endocrinology

ea0016p521 | Obesity | ECE2008

Expression of adrenergic receptors and atrial natriuretic peptide in human adipose tissue of severe obese women and Rosiglitazone action during differentiation of human pre-adipocytes

Garruti Gabriella , Giusti Vittorio , Nussberger Jurg , Darimont Christian , Appert-Collin Aline , Perrini Sebastiano , NennigerTosato Monique , Giorgino Riccardo , Giorgino Francesco , Cotecchia Susanna

Background: The balance between Adrenergic Receptor (AR) subtypes and Atrial Natriuretic Peptide (ANP) is crucial for lipolysis. It was previously demonstrated that ANP is strongly lipolytic and we recently demonstrated that ANP is expressed and secreted by human pre-adipocytes. In previous studies, β-receptor density and lipolysis were higher in human visceral adipose tissue (HVAT) as compared with human subcutaneous adipose tissue (HSAT).Aims and ...

ea0086oc1.6 | Bone and Calcium | SFEBES2022

The AXT914 calcilytic compound increases plasma calcium and PTH in a mouse model for autosomal dominant hypocalcaemia type 1 (ADH1)

Kooblall Kreepa , Hannan Fadil , Stevenson Mark , Lines Kate , Meng Xin , Stewart Michelle , Wells Sara , Gasser Jurg , Thakker Rajesh

Heterozygous germline gain-of-function mutations of the extracellular calcium-sensing receptor (CaSR), a G-protein coupled receptor (GPCR), result in autosomal dominant hypocalcaemia type 1 (ADH1), which may cause symptomatic hypocalcaemia with low circulating parathyroid hormone (PTH) concentrations and hypercalciuria. Negative allosteric CaSR modulators, known as calcilytics, rectify the gain-of-function caused by CaSR mutations and are a potential targeted therapy for ADH1....